Edition:
United States

Masimo Corp (MASI.O)

MASI.O on Nasdaq

88.23USD
10:31am EST
Change (% chg)

$0.90 (+1.03%)
Prev Close
$87.33
Open
$87.60
Day's High
$88.33
Day's Low
$87.43
Volume
17,802
Avg. Vol
476,592
52-wk High
$104.71
52-wk Low
$60.31

Chart for

About

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company's business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings... (more)

Overall

Beta: 0.74
Market Cap(Mil.): $4,512.44
Shares Outstanding(Mil.): 51.67
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 51.53 15.49
EPS (TTM): -- -- --
ROI: -- 13.47 11.95
ROE: -- 19.97 15.94

BRIEF-‍San Diego bankruptcy court issues final judgment on Masimo Corp

* Masimo Corp - ‍Bankruptcy court in San Diego has issued final judgment, holding that "Sotera Wireless employees misappropriated Masimo trade secrets"​ Source text for Eikon: Further company coverage:

Oct 16 2017

BRIEF-Masimo reports FDA clearance and full market release of rad-97 pulse co-oximeter

* Masimo announces FDA clearance and full market release of rad-97™ pulse co-oximeter® Source text for Eikon: Further company coverage:

Sep 18 2017

BRIEF-Masimo says CFO Mark De Raad to retire ‍​

* Masimo Corp - On August 23, Mark P. De Raad, CFO, notified co of his intention to retire and resign from his roles with the company‍​ ‍​

Aug 24 2017

BRIEF-Dubai Health Authority implementiert Masimo Patient SafetyNet

* Dubai Health Authority implementiert Masimo Patient SafetyNet Source text for Eikon: Further company coverage:

Aug 15 2017

BRIEF-Masimo Q2 earnings per share $0.83

* Q2 earnings per share view $0.71 -- Thomson Reuters I/B/E/S

Aug 02 2017

BRIEF-Masimo Corp says appears co addressed violations contained in FDA warning letter regarding Irvine facility

* Masimo - ‍on May 26, received letter from FDA indicating FDA has completed an evaluation of Masimo's corrective actions in response to warning letter​

Jun 06 2017

Earnings vs. Estimates